U.S. Media Stock News

Marzetti (MZTI) has just posted its Q3 2026 scorecard, with revenue of US$453.4 million and basic EPS of US$1.35, while the trailing twelve months show total revenue of about US$1.9 billion and EPS of US$6.40. Over recent quarters, revenue has ranged between US$457.8 million and US$518.0 million with quarterly EPS between US$1.18 and US$2.15. Taken together, this sets up a picture where headline growth expectations and the latest profit print now sit alongside a 9.1% net margin that frames...

If you are wondering whether Thermo Fisher Scientific at around US$472.95 is genuinely good value or just pricing in high expectations, the starting point is to look closely at what the current valuation is really saying. The stock has returned 1.4% over the last 7 days, a 3.1% decline over the last 30 days, a 20.2% decline year to date, but a 16.4% gain over the last year, which gives a mixed picture of sentiment and risk appetite over different time frames. Recent headlines have focused on...

Gartner (IT) has put fresh numbers on the board for Q1 2026, reporting revenue of US$1.5b and basic EPS of US$3.19 off net income of US$222.3m, setting the tone for how you might think about the rest of the year. Over recent quarters the company has seen revenue move between US$1.5b and US$1.8b, while quarterly EPS has ranged from US$0.47 to US$5.14, providing a clear view of how earnings power has fluctuated into this latest print. With trailing net margins now sitting well below last year’s...

Northrop Grumman (NYSE:NOC) has been selected by the Australian government to establish domestic solid rocket motor production. The agreement focuses on building local capability for advanced propulsion systems used in long range strike weapons. This marks an expansion of Northrop Grumman's solid rocket motor footprint outside the U.S. and deepens its role in allied defense supply chains. For investors tracking NYSE:NOC, this move extends the company's defense manufacturing reach into a key...

If you are wondering whether SoFi Technologies at around US$16.30 is starting to look expensive or still offers value, it helps to step back and look at what the recent price action and fundamentals are really saying. The stock has seen mixed returns, with a 5.0% move over the last 7 days, 0.2% over 30 days, a 40.6% decline year to date, and a 25.3% return over the past year. These shifts can change how investors think about both its growth potential and risk. Recent coverage has focused on...

If you are wondering whether Edwards Lifesciences at around US$83.20 still offers value, the key question is how its current price stacks up against what the business may be worth. The stock has returned 2.4% over the past week and 2.5% over the past month, with a 10.9% return over the last year but a year to date return of 2.5% decline and softer 3 year and 5 year returns of 6.4% and 4.9% declines. Recent headlines around Edwards Lifesciences have focused on its role in the broader medical...

Weis Markets has reported past first-quarter 2026 results showing sales of US$1,251.72 million and net income of US$27.85 million, alongside a reaffirmed quarterly dividend of US$0.34 per share payable on May 26, 2026. The strong year-over-year increase in earnings per share from US$0.73 to US$1.13 points to improved profitability despite only modest revenue growth. We’ll now look at how Weis Markets’ sharp earnings per share improvement shapes its investment narrative and potential...

Rambus (RMBS) has drawn fresh attention after launching a PCIe 7.0 Switch IP with Time Division Multiplexing, aimed at addressing bandwidth, latency, and scalability needs in AI, cloud, and high performance computing systems. See our latest analysis for Rambus. The PCIe 7.0 Switch IP news lands during a sharp upswing in Rambus’s share price, with a 1 day share price return of 10.20% and a 30 day share price return of 41.01%. The 1 year total shareholder return is very large, suggesting...

Novavax, Inc. has reported past first-quarter 2026 results showing revenue of US$139.51 million, down sharply from US$666.66 million a year earlier, and a net loss of US$9.49 million compared with prior net income of US$518.65 million. The swing from earnings per share of US$3.22 to a basic loss of US$0.06 highlights how quickly Novavax’s profitability profile has shifted as its business mix changes. Next, we’ll examine how this sharp year-on-year revenue drop and move into loss-making...

If you are wondering whether NuScale Power's current share price reflects its true worth, this article will help you size up the stock using several valuation tools. The stock recently closed at US$11.87, with returns of 0.4% over 7 days, 16.9% over 30 days, a 27.2% decline year to date, a 32.8% decline over 1 year, 47.6% over 3 years and 19.8% over 5 years. This gives you a wide range of outcomes to think about. Recent coverage has focused on NuScale Power's role in nuclear energy...

Guardant Health’s Guardant360 CDx liquid biopsy has received FDA approval as a companion diagnostic for VEPPANU, a therapy for ER+/HER2- advanced breast cancer with ESR1 mutations. This is the third ESR1 companion diagnostic approval tied to Guardant360 CDx, further linking the test to targeted breast cancer treatments. The new approval broadens the clinical use of Guardant360 CDx and deepens Guardant Health’s ties with pharmaceutical partners. For investors tracking Guardant Health...

Alkermes Q1 2026 earnings: setting the stage Alkermes (ALKS) heads into Q1 2026 following its Q4 2025 report, where revenue was US$384.5 million and basic EPS came in at US$0.30, with net income excluding extra items of US$49.3 million. Over recent quarters, the company has reported revenue of US$429.99 million in Q4 2024, US$390.7 million in Q2 2025, and US$394.2 million in Q3 2025. Quarterly basic EPS over that period was US$0.90 in Q4 2024, US$0.50 in Q3 2025, and US$0.30 in Q4 2025. These...

Tango Therapeutics recently outlined leadership changes, including appointing Malte Peters as CEO and moving Barbara Weber to Executive Chair, alongside plans for pivotal trials and a pan-RAS supply agreement, while also granting equity awards to its new CFO and another employee under its 2023 Inducement Plan. These developments highlight how Tango’s evolving leadership structure and long-term incentive grants are being aligned with upcoming clinical milestones and partnership...

Fresh Del Monte Produce (FDP) opened 2026 with mixed momentum, coming off Q4 2025 revenue of US$1.0 billion and basic EPS of US$0.67 on net income of US$31.9 million, while trailing 12 month EPS sat at US$1.90 on net income of US$90.7 million from US$4.3 billion in revenue. Over recent quarters the company has seen quarterly revenue move between US$1.0 billion and US$1.2 billion, with basic EPS ranging from a loss of US$0.61 in Q3 2025 to a high of US$1.18 in Q2 2025, alongside trailing 12...

Investors may be wondering if Compañía de Minas BuenaventuraA at around US$31.98 still offers value after a strong run, or if most of the opportunity has already been priced in. The stock has returned 2.8% over the last 7 days, moved by 12.2% over the last month, is up 11.9% year to date, 114.5% over 1 year and has a very large 3 year return that is roughly 4x, with a 5 year return of 214.8%. Recent attention on the stock has been driven by ongoing interest in metals and mining companies and...

In late April and early May 2026, Gen Digital’s Norton brand rolled out major upgrades to its AI-native Norton Neo browser and related AI security tools, embedding built-in VPN, anti-phishing, anti-fingerprinting, and AI agent protections, while also expanding partnerships with xAI and Microsoft for secure AI and financial experiences. These launches, combined with new AI agent-focused VPN offerings and fresh third‑party awards for Norton, Avast, AVG, and Avira, highlight Gen’s push to...

Seadrill stock snapshot after recent performance Seadrill (SDRL) has drawn fresh attention after recent trading, with the stock last closing at US$48.90 and showing mixed short term returns, including a 0.9% decline over the past day and 1.8% decline over the past week. See our latest analysis for Seadrill. While Seadrill’s 1 day and 7 day share price returns are slightly negative, the 30 day and 90 day share price returns of 7.2% and 23.5%, together with a 1 year total shareholder return of...

Q1 earnings reset expectations, but losses continue Lumen Technologies (LUMN) reported first quarter 2026 sales of US$2,899 million, compared with US$3,182 million a year earlier. Net loss was US$200 million versus US$201 million, keeping loss per share steady at US$0.20. See our latest analysis for Lumen Technologies. The share price has been volatile around these Q1 results, with a 1 month share price return of 32.05% and a 90 day share price return of 39.22%. The 1 year total shareholder...

Revvity Q1 2026 earnings snapshot Revvity (RVTY) has just put fresh numbers on the table, with recent quarters showing revenue between US$664.8 million and US$772.1 million and basic EPS ranging from US$0.35 to US$0.85 as the company heads into its Q1 2026 update. Over the past year, revenue has been recorded from US$684.0 million in Q3 2024 up to US$772.1 million in Q4 2025, while basic EPS prints in that stretch run from US$0.35 to US$0.85, giving investors a clear view of how the top line...

Why Fermi (FRMI) is on investors’ radar Fermi (FRMI) has been drawing attention after recent share price moves, with the stock last closing at $4.94 and a market value around $3.19b. This has put its AI-focused power campus model in sharper focus. See our latest analysis for Fermi. Recent trading has been weak, with a 1 day share price return of a 2.56% decline adding to a 90 day share price return of a 39.61% decline. This suggests negative momentum as investors reassess growth prospects and...

In late April 2026, Monolithic Power Systems reported first-quarter 2026 revenue of US$804.19 million and net income of US$193.23 million, raised second-quarter revenue guidance to US$890–910 million with GAAP gross margin of 55.1–55.7%, and secured a favorable resolution of a Bel Power patent lawsuit with US$50,000 in court costs awarded. Beyond the headline beats, the quarter underscored how Monolithic Power Systems’ enterprise data and communications power solutions, backed by...

Clinical partnership puts Vir Biotechnology in focus Vir Biotechnology (VIR) has drawn fresh attention after finalizing its collaboration with Astellas Pharma on VIR-5500 for prostate cancer and treating the first patient in an expansion cohort of its Phase 1 metastatic prostate cancer trial. See our latest analysis for Vir Biotechnology. The recent collaboration news comes against a backdrop of strong momentum, with a 30 day share price return of 10.49% and a year to date share price return...

Two Harbors Investment (NYSE:TWO) is the subject of a takeover battle involving competing bids from UWM Holdings and CrossCountry Mortgage. The board of NYSE:TWO has rejected multiple acquisition attempts from UWM Holdings and is backing a fully financed, all-cash offer from CrossCountry Mortgage. The contest now centers on a shareholder vote, proxy solicitations, and competing arguments about value, deal structure, and execution risk. For you as a NYSE:TWO shareholder, this is not a...

Wondering if Ally Financial at around US$43 per share still offers value, or if most of the easy gains are behind it, starts with understanding what the current price is actually reflecting. The stock has had mixed recent returns, with a 2.7% decline over the last week, an 8.5% gain over the last month, a 5.6% decline year to date, and a 36.8% return over the last year alongside an 88.9% three year return and a 2.9% five year decline. Recent coverage has focused on how Ally Financial fits...